# Caribou Biosciences to Participate in the 2026 Jefferies Global Healthcare Conference
Canonical URL: https://biopharmsignal.com/news/CRBU/caribou-biosciences-to-participate-in-the-2026-jefferies-global-healthcare-conference
Ticker: CRBU
Company: Caribou
Source: Caribou
Published: 2026-06-25 13:46 EST
Original Source URL: https://investor.cariboubio.com
## Summary

BERKELEY, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou’s president and chief executive officer, will participate in a fireside chat at the

## Article Body
BERKELEY, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou’s president and chief executive officer, will participate in a fireside chat at the
## Recent Company News
- 2026-06-29 12:00 EST — [Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference](https://biopharmsignal.com/news/CRBU/caribou-biosciences-to-participate-in-the-h-c-wainwright-4th-annual-cell-therapy-faa61d70) — Source: Caribou
- 2026-06-25 13:46 EST — [Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual Meeting](https://biopharmsignal.com/news/CRBU/caribou-biosciences-reports-dose-escalation-durability-data-for-cb-011-at-the-2026-european-hematology-association-eha-annual-meeting) — Source: Caribou
- 2026-06-25 13:46 EST — [Caribou Biosciences Reports Long-Term Vispa-cel Data in Second-line Large B Cell Lymphoma at EHA 2026](https://biopharmsignal.com/news/CRBU/caribou-biosciences-reports-long-term-vispa-cel-data-in-second-line-large-b-cell-lymphoma-at-eha-2026) — Source: Caribou
- 2026-06-25 13:46 EST — [Caribou Biosciences to Participate in the 2026 Jefferies Global Healthcare Conference](https://biopharmsignal.com/news/CRBU/caribou-biosciences-to-participate-in-the-2026-jefferies-global-healthcare-conference) — Source: Caribou
- 2026-06-25 13:46 EST — [Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference](https://biopharmsignal.com/news/CRBU/caribou-biosciences-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference) — Source: Caribou
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)